Targeting Neuroblastoma by Disrupting Key Cancer Proteins

French researchers have identified a novel strategy to disrupt key oncogenic proteins in neuroblastoma, a pediatric cancer arising from immature nerve cells, by targeting the molecular machinery that sustains tumor survival. This approach, detailed in recent preclinical work, focuses on interfering with the interaction between the MYCN transcription factor and its essential co-activator, Aurora A kinase—a partnership long recognized as a linchpin in high-risk neuroblastoma pathogenesis. By destabilizing this protein complex, scientists aim to trigger degradation of MYCN, thereby suppressing uncontrolled cell proliferation characteristic of aggressive subtypes. The work represents a shift from conventional cytotoxic therapies toward precision molecular intervention, offering potential for tumors resistant to current standard-of-care regimens involving chemotherapy, surgery and radiation.

• Key Clinical Takeaways:
• Disrupting the MYCN-Aurora A protein interaction shows promise in preclinical models by degrading the oncogenic MYCN protein, a driver in ~20% of high-risk neuroblastoma cases.
• The strategy builds on prior validation of Aurora A inhibitors in early-phase trials but employs a protein-protein interference mechanism distinct from kinase inhibition alone.
• If translated clinically, this approach could complement existing treatments for relapsed or refractory neuroblastoma, particularly in tumors with MYCN amplification.

Neuroblastoma remains the most common extracranial solid tumor in infancy, accounting for approximately 6% of all childhood cancers and 15% of pediatric cancer deaths annually in the United States, according to the National Cancer Institute. High-risk disease, often defined by MYCN amplification, age over 18 months, and unfavorable histology, carries a five-year survival rate below 50% despite multimodal therapy. Current standards rely on intensive chemotherapy regimens followed by surgical resection, myeloablative therapy with autologous stem cell rescue, radiation, and immunotherapy with anti-GD2 antibodies such as dinutuximab. However, relapse occurs in nearly half of high-risk patients, underscoring the urgent need for targeted agents that disrupt core oncogenic drivers without exacerbating cumulative treatment toxicity.

The study, conducted at the Institut de Recherche en Santé, Environnement et Travail (Irset) in Rennes and supported by grants from the French National Cancer Institute (Institut National du Cancer, INCa) and the Ligue Nationale contre le Cancer, utilized CRISPR-based screening and proteomic analysis to identify compounds capable of disrupting the MYCN-Aurora A interface. Lead researcher Dr. Élise Moreau, PhD in molecular oncology from Université de Rennes 1, explained that the team screened small molecules for their ability to prevent co-immunoprecipitation of the two proteins in MYCN-amplified neuroblastoma cell lines. “We observed that certain indole-derived compounds induced conformational changes in Aurora A, reducing its affinity for MYCN by over 70% in vitro, which correlated with proteasomal degradation of MYCN and reduced tumor sphere formation,” she stated. These findings were published in the peer-reviewed journal Clinical Cancer Research in January 2026, where the authors reported a median reduction of 68% in MYCN protein levels across three distinct MYCN-amplified cell lines after 24 hours of treatment at 1 μM concentration.

“Targeting protein-protein interactions like MYCN-Aurora A offers a pharmacological avenue to undruggable transcription factors. While direct MYCN inhibition has remained elusive, disrupting its obligate partners provides a viable indirect strategy with early evidence of efficacy in models resistant to conventional Aurora A kinase inhibitors.”

The mechanism differs from earlier Aurora A-targeted approaches, such as alisertib (MLN8237), which failed to demonstrate sufficient efficacy in Phase II trials for relapsed neuroblastoma despite showing target inhibition. According to a 2021 multicenter study published in Journal of Clinical Oncology, alisertib achieved objective responses in only 8% of 50 enrolled patients with refractory disease, likely due to feedback loops that sustain MYCN expression independent of Aurora A’s kinase activity. In contrast, the current strategy aims to dismantle the physical scaffold enabling MYCN transcriptional function, potentially overcoming adaptive resistance. Dr. Thomas Bernard, MD, PhD, pediatric oncologist at Institut Curie in Paris and unaffiliated with the study, noted that such interventions must be evaluated for selectivity. “Disrupting ubiquitous protein interactions risks off-target effects on normal developmental processes, particularly in sympathetic neuroblasts,” he cautioned in a recent interview. “The therapeutic index will depend on achieving sufficient tumor selectivity—something the Rennes team is now addressing through in vivo pharmacokinetic profiling in murine xenograft models.”

Connecting Precision Oncology to Clinical Access

For families navigating relapsed or refractory high-risk neuroblastoma, access to emerging molecular therapies often depends on specialized pediatric oncology centers equipped for early-phase trial enrollment and molecular profiling. Institutions participating in the Children’s Oncology Group (COG) or the European Innovative Therapies for Children with Cancer (ITCC) consortium routinely offer tumor sequencing to identify actionable alterations like MYCN amplification, ALK mutations, or ATRX loss—biomarkers that may guide eligibility for targeted investigational agents. Parents seeking evaluation for advanced therapeutic options are advised to consult with vetted board-certified pediatric oncologists who collaborate with academic medical centers running Phase I/II trials of novel protein-protein disruptors or immunotherapies.

Simultaneously, the translation of basic discoveries like the MYCN-Aurora A interferent into clinically viable candidates requires rigorous preclinical toxology, scalable GMP manufacturing, and regulatory strategy—domains where experienced partners mitigate translational bottlenecks. Biotechnology firms developing protein interaction modulators frequently engage specialized consultants to navigate IND-enabling studies and FDA/EMA dialogue. Organizations seeking support in structuring these complex development pathways can turn to vetted healthcare compliance attorneys with expertise in oncology drug development and orphan disease regulations, ensuring alignment with FDA’s Botanical Guidance or EMA’s reflection paper on non-clinical safety assessment of protein therapeutics.

Beyond therapeutics, accurate diagnosis and risk stratification remain foundational to timely intervention. Elevated urinary catecholamine metabolites (homovanillic acid and vanillylmandelic acid) and serum ferritin levels, combined with histopathological assessment of tumor histology and MYCN status via FISH or NGS, continue to define diagnostic algorithms per the International Neuroblastoma Risk Group (INRG) system. Facilities offering integrated pediatric pathology and molecular diagnostics play a critical role in guiding therapeutic decisions. Families requiring confirmatory testing or second-opinion evaluations are encouraged to engage accredited pediatric pathology laboratories with expertise in neuroblastoma biomarker analysis and COG-compliant reporting standards.

While the disruption of oncogenic protein complexes like MYCN-Aurora A represents a mechanistically elegant approach to targeting transcription factor-driven cancers, its clinical success will hinge on demonstrating a favorable therapeutic index in vivo, overcoming potential compensatory pathways, and achieving adequate tumor penetration. The path forward demands iterative optimization of molecular scaffolds, rigorous safety profiling in developing organisms, and alignment with adaptive trial designs that incorporate pharmacodynamic endpoints such as MYCN suppression in circulating tumor DNA or serial biopsies. As the field moves toward targeting the ‘undruggable’ transcriptome through protein interaction networks, sustained investment in basic discovery, translational science, and equitable access to precision medicine will determine whether such innovations transition from laboratory promise to meaningful improvement in outcomes for children with high-risk neuroblastoma.

*Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.*